Status:
UNKNOWN
Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19
Lead Sponsor:
Universidade Federal do Ceara
Collaborating Sponsors:
Conselho Nacional de Desenvolvimento Científico e Tecnológico
São José Hospital for Infectious Diseases - HSJ
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Clinical, control, double-blind, randomized trial with tenofovir disoproxyl fumarate and emtricitabine for Covid-19
Detailed Description
Several therapeutic agents have been evaluated for the treatment of Covid-19, and only one using an antiviral drug called remdesivir administered intravenously has shown efficacy to reduce the duratio...
Eligibility Criteria
Inclusion
- Patient is \> 18 years old
- Patient diagnosed with COVID-19
Exclusion
- Patient is already receiving some of the study drugs
- There is a hospitalization plan in the next 24h
- Some study treatment is contraindicated
- Patient has HIV infection
- Patient has VHB infection
- Patient lives in another city or state
- Female patient, pregnant
Key Trial Info
Start Date :
November 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
219 Patients enrolled
Trial Details
Trial ID
NCT04712357
Start Date
November 9 2020
End Date
January 1 2023
Last Update
January 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Núcleo de Biomedicina - NUBIMED
Fortaleza, Ceará, Brazil, 60430270